
New targeted drug more than doubles time before HER2-low breast cancer grows
A phase 3 trial of 551 women in China found trastuzumab rezetecan delayed HER2-low breast cancer growth to 16.4 months versus 6.8 on chemotherapy, with more side effects.
Peepals Shakti · Topic
7 stories, newest first

A phase 3 trial of 551 women in China found trastuzumab rezetecan delayed HER2-low breast cancer growth to 16.4 months versus 6.8 on chemotherapy, with more side effects.

A McMaster University study of over one million Ontario pregnancies, published on 22 October 2026, links gaining more weight than advised to severe maternal complications.

A MUSC study in JAMA Pediatrics, announced on October 19, 2026, finds US teenage girls have vaped regularly at higher rates than boys since 2021.

A University of Sydney study published October 14, 2026 found recorded family violence against Australian children rose 8-20% a year from about 2020.

A JAMA Neurology study published October 12, 2026 links early-pregnancy use of anti-CGRP migraine antibodies to about 40% higher miscarriage risk.

A Northwestern trial of 405 women found patient navigators raised postpartum visit attendance to 96% from 80% and nearly doubled primary care follow-up.

Teens with at least one trusted person to talk to had much lower depression and suicidal thoughts, a JAMA Pediatrics study published 12 October 2026 found.
The most important, fact-checked stories from all seven publications, once a week.